FME.DE Fresenius Medical Care XETRA 19 Feb 2026 earnings preview: catalysts

FME.DE stock trades at €41.15 on XETRA intraday as Fresenius Medical Care prepares to report earnings on 24 Feb 2026. Investors will focus on margin trends in dialysis services, U.S. hospital contract renewals and product sales growth. The stock is down 0.21 euros today with a day range of €40.74–€41.31, but year-to-date performance is essentially flat. With EPS at €2.44 and a trailing PE of 16.55, the upcoming report could shift sentiment for a healthcare name that mixes stable cash flow and leverage.

FME.DE stock: earnings timetable and what to watch

FME.DE stock has an earnings announcement set for 24 Feb 2026; key items to watch are organic revenue growth in dialysis clinics and margins in North America. Management commentary on clinic volumes and supply sales will matter because dialysis services drive recurring revenue and influence the PE 16.55 multiple. Expect questions on price pressure, reimbursement, and any update to guidance; one strong beat or miss could move the stock more than its typical intraday ATR of €0.88.

FME.DE stock: intraday price action and liquidity

Intraday, FME.DE stock is at €41.15 after opening at €40.74, with a session high of €41.31 and low of €40.74. Volume stands at 65,748 versus an average of 861,101, so liquidity is light today and traders should expect larger spreads around the print. Short-term support sits near the 50-day average of €39.39 and resistance near the 200-day average of €43.79.

FME.DE stock: valuation and cash flow metrics

FME.DE stock trades at a price-to-sales of 0.61, price-to-book of 0.92, and EV/EBITDA of 6.76, indicating value metrics versus many healthcare peers. Free cash flow yield is 14.79% and the dividend yield is approximately 3.52% on a payout ratio of 58.83%. Net debt to EBITDA sits near 2.93x, and debt-to-equity is 0.81, so the balance sheet is levered but supported by steady cash generation.

FME.DE stock: Meyka AI grade and analyst context

Meyka AI rates FME.DE with a score out of 100: 72.03 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Note other third-party company ratings show mixed signals — a recent company rating dated 18 Feb 2026 lists B+ with a neutral recommendation on some metrics — so investors should weigh growth versus leverage. These grades are not guaranteed and we are not financial advisors.

FME.DE stock: technicals and short-term trading signals

Momentum indicators on FME.DE stock show RSI at 55.97 and MACD histogram positive at 0.23, suggesting mild upside bias into the report. Bollinger Bands read €36.16–€42.33, implying volatility could expand. Short-term traders should note on-balance volume and MFI are elevated, so a strong print could trigger follow-through; conversely, a weak beat could push the stock toward the €35.67 yearly low.

FME.DE stock: risks and catalysts ahead of the report

Catalysts for FME.DE stock include U.S. clinic volume recovery, stronger dialysis product sales, and margin improvement from cost controls. Risks are reimbursement changes, contract renewals in key markets, and FX headwinds from the U.S. dollar. Rising interest rates would pressure valuation given leverage, while any positive guidance lift could re-rate the shares toward peer multiples.

Final Thoughts

Key takeaways for FME.DE stock ahead of the 24 Feb earnings: the shares trade at €41.15 on XETRA with a moderate value profile (PE 16.55, EV/EBITDA 6.76) and a 3.52% dividend yield. Meyka AI’s forecast model projects a one-year path to €44.36, implying an upside of 7.81% versus the current price; shorter-term model points are €37.75 (monthly, downside ‑8.26%) and €33.25 (quarterly, downside ‑19.19%). Use the report to test revenue durability and cash generation; a clean beat could validate the Meyka grade and push the price toward €46.00–€50.00 near-term, while a weak outlook could reopen the low-€30s. Forecasts are model-based projections and not guarantees. For live updates and a consolidated view of the print, see the latest press coverage on PR Newswire and MarketBeat and check the FME.DE stock page on Meyka for real-time tools and alerts.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.